trial

Metacognitive Training and Insight in Schizophrenia

NCTId NCT04104347
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 252 (estimated)
Sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Primary completion 2020-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
252 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2019-06-10
Primary completion
2020-12-31
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Metacognitive Training (MCT)Support group

Sponsors

Instituto de Investigación Sanitaria de la Fundación Jiménez DíazLead Sponsor
Universidad Autonoma de MadridCollaborator

Investigators

1
Javier-David Lopez-Morinigo, MB BS, PhDPrincipal Investigator

Sites

1 total
Madrid, Spain

Facts & assertions

4 sourced
Enrollment
252
Phase
NA
Primary Completion Date
2020-12-31
Status
UNKNOWN
relationships
The graph out of here
drug
Metacognitive Training (MCT)
drug
Support group
drug
lead_sponsor
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
company
collaborator
Universidad Autonoma de Madrid
company
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
investigator
Javier-David Lopez-Morinigo, MB BS, PhD
person